nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Myalgia—Gemcitabine—pancreatic cancer	0.00151	0.00209	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.0015	0.00207	CcSEcCtD
Apraclonidine—Asthenia—Erlotinib—pancreatic cancer	0.0015	0.00207	CcSEcCtD
Apraclonidine—Discomfort—Gemcitabine—pancreatic cancer	0.0015	0.00206	CcSEcCtD
Apraclonidine—Pruritus—Tamoxifen—pancreatic cancer	0.00149	0.00206	CcSEcCtD
Apraclonidine—Oedema—Irinotecan—pancreatic cancer	0.00149	0.00205	CcSEcCtD
Apraclonidine—Myalgia—Fluorouracil—pancreatic cancer	0.00149	0.00205	CcSEcCtD
Apraclonidine—Chest pain—Fluorouracil—pancreatic cancer	0.00149	0.00205	CcSEcCtD
Apraclonidine—Infection—Irinotecan—pancreatic cancer	0.00148	0.00204	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00148	0.00204	CcSEcCtD
Apraclonidine—Pruritus—Erlotinib—pancreatic cancer	0.00148	0.00204	CcSEcCtD
Apraclonidine—Discomfort—Fluorouracil—pancreatic cancer	0.00147	0.00203	CcSEcCtD
Apraclonidine—Nervous system disorder—Irinotecan—pancreatic cancer	0.00146	0.00201	CcSEcCtD
Apraclonidine—Rhinitis—Docetaxel—pancreatic cancer	0.00145	0.002	CcSEcCtD
Apraclonidine—Oedema—Gemcitabine—pancreatic cancer	0.00145	0.002	CcSEcCtD
Apraclonidine—Haemorrhage—Docetaxel—pancreatic cancer	0.00145	0.002	CcSEcCtD
Apraclonidine—Eye pain—Doxorubicin—pancreatic cancer	0.00145	0.002	CcSEcCtD
Apraclonidine—Diarrhoea—Tamoxifen—pancreatic cancer	0.00145	0.00199	CcSEcCtD
Apraclonidine—Infection—Gemcitabine—pancreatic cancer	0.00144	0.00199	CcSEcCtD
Apraclonidine—Pharyngitis—Docetaxel—pancreatic cancer	0.00144	0.00198	CcSEcCtD
Apraclonidine—Abdominal pain—Sunitinib—pancreatic cancer	0.00143	0.00197	CcSEcCtD
Apraclonidine—Diarrhoea—Erlotinib—pancreatic cancer	0.00143	0.00197	CcSEcCtD
Apraclonidine—Oedema peripheral—Docetaxel—pancreatic cancer	0.00143	0.00197	CcSEcCtD
Apraclonidine—Oedema—Fluorouracil—pancreatic cancer	0.00143	0.00197	CcSEcCtD
Apraclonidine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00142	0.00196	CcSEcCtD
Apraclonidine—Infection—Fluorouracil—pancreatic cancer	0.00142	0.00195	CcSEcCtD
Apraclonidine—Skin disorder—Gemcitabine—pancreatic cancer	0.00141	0.00194	CcSEcCtD
Apraclonidine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.0014	0.00193	CcSEcCtD
Apraclonidine—Visual impairment—Docetaxel—pancreatic cancer	0.0014	0.00193	CcSEcCtD
Apraclonidine—Dizziness—Tamoxifen—pancreatic cancer	0.0014	0.00193	CcSEcCtD
Apraclonidine—Dizziness—Erlotinib—pancreatic cancer	0.00138	0.00191	CcSEcCtD
Apraclonidine—Face oedema—Epirubicin—pancreatic cancer	0.00137	0.00188	CcSEcCtD
Apraclonidine—Eye disorder—Docetaxel—pancreatic cancer	0.00136	0.00187	CcSEcCtD
Apraclonidine—Insomnia—Irinotecan—pancreatic cancer	0.00135	0.00186	CcSEcCtD
Apraclonidine—Vomiting—Tamoxifen—pancreatic cancer	0.00134	0.00185	CcSEcCtD
Apraclonidine—Paraesthesia—Irinotecan—pancreatic cancer	0.00134	0.00184	CcSEcCtD
Apraclonidine—Hypersensitivity—Sunitinib—pancreatic cancer	0.00133	0.00184	CcSEcCtD
Apraclonidine—Dermatitis—Tamoxifen—pancreatic cancer	0.00133	0.00183	CcSEcCtD
Apraclonidine—Vomiting—Erlotinib—pancreatic cancer	0.00133	0.00183	CcSEcCtD
Apraclonidine—Dyspnoea—Irinotecan—pancreatic cancer	0.00133	0.00183	CcSEcCtD
Apraclonidine—Somnolence—Irinotecan—pancreatic cancer	0.00133	0.00183	CcSEcCtD
Apraclonidine—Headache—Tamoxifen—pancreatic cancer	0.00132	0.00182	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00132	0.00182	CcSEcCtD
Apraclonidine—Dermatitis—Erlotinib—pancreatic cancer	0.00132	0.00181	CcSEcCtD
Apraclonidine—Angiopathy—Docetaxel—pancreatic cancer	0.00132	0.00181	CcSEcCtD
Apraclonidine—Insomnia—Gemcitabine—pancreatic cancer	0.00131	0.00181	CcSEcCtD
Apraclonidine—Headache—Erlotinib—pancreatic cancer	0.00131	0.0018	CcSEcCtD
Apraclonidine—Mediastinal disorder—Docetaxel—pancreatic cancer	0.00131	0.0018	CcSEcCtD
Apraclonidine—Paraesthesia—Gemcitabine—pancreatic cancer	0.0013	0.0018	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.0013	0.00179	CcSEcCtD
Apraclonidine—Asthenia—Sunitinib—pancreatic cancer	0.0013	0.00179	CcSEcCtD
Apraclonidine—Arrhythmia—Docetaxel—pancreatic cancer	0.0013	0.00179	CcSEcCtD
Apraclonidine—Dyspnoea—Gemcitabine—pancreatic cancer	0.00129	0.00178	CcSEcCtD
Apraclonidine—Insomnia—Fluorouracil—pancreatic cancer	0.00129	0.00178	CcSEcCtD
Apraclonidine—Somnolence—Gemcitabine—pancreatic cancer	0.00129	0.00178	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00129	0.00177	CcSEcCtD
Apraclonidine—Fatigue—Irinotecan—pancreatic cancer	0.00129	0.00177	CcSEcCtD
Apraclonidine—Paraesthesia—Fluorouracil—pancreatic cancer	0.00128	0.00177	CcSEcCtD
Apraclonidine—Pruritus—Sunitinib—pancreatic cancer	0.00128	0.00176	CcSEcCtD
Apraclonidine—Pain—Irinotecan—pancreatic cancer	0.00127	0.00176	CcSEcCtD
Apraclonidine—Constipation—Irinotecan—pancreatic cancer	0.00127	0.00176	CcSEcCtD
Apraclonidine—Dyspnoea—Fluorouracil—pancreatic cancer	0.00127	0.00175	CcSEcCtD
Apraclonidine—Mental disorder—Docetaxel—pancreatic cancer	0.00127	0.00175	CcSEcCtD
Apraclonidine—Somnolence—Fluorouracil—pancreatic cancer	0.00127	0.00175	CcSEcCtD
Apraclonidine—Nasopharyngitis—Epirubicin—pancreatic cancer	0.00126	0.00174	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—pancreatic cancer	0.00126	0.00174	CcSEcCtD
Apraclonidine—Erythema—Docetaxel—pancreatic cancer	0.00126	0.00174	CcSEcCtD
Apraclonidine—Nausea—Tamoxifen—pancreatic cancer	0.00125	0.00173	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00125	0.00173	CcSEcCtD
Apraclonidine—Fatigue—Gemcitabine—pancreatic cancer	0.00125	0.00173	CcSEcCtD
Apraclonidine—Pain—Gemcitabine—pancreatic cancer	0.00124	0.00171	CcSEcCtD
Apraclonidine—Constipation—Gemcitabine—pancreatic cancer	0.00124	0.00171	CcSEcCtD
Apraclonidine—Nausea—Erlotinib—pancreatic cancer	0.00124	0.00171	CcSEcCtD
Apraclonidine—Diarrhoea—Sunitinib—pancreatic cancer	0.00124	0.00171	CcSEcCtD
Apraclonidine—Dysgeusia—Docetaxel—pancreatic cancer	0.00124	0.0017	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00123	0.0017	CcSEcCtD
Apraclonidine—Feeling abnormal—Irinotecan—pancreatic cancer	0.00123	0.00169	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—pancreatic cancer	0.00122	0.00168	CcSEcCtD
Apraclonidine—Pain—Fluorouracil—pancreatic cancer	0.00122	0.00168	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00122	0.00168	CcSEcCtD
Apraclonidine—Dizziness—Sunitinib—pancreatic cancer	0.0012	0.00165	CcSEcCtD
Apraclonidine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.0012	0.00165	CcSEcCtD
Apraclonidine—Abdominal pain—Irinotecan—pancreatic cancer	0.00118	0.00162	CcSEcCtD
Apraclonidine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00118	0.00162	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.00117	0.00161	CcSEcCtD
Apraclonidine—Vomiting—Sunitinib—pancreatic cancer	0.00115	0.00159	CcSEcCtD
Apraclonidine—Dermatitis—Sunitinib—pancreatic cancer	0.00114	0.00157	CcSEcCtD
Apraclonidine—Headache—Sunitinib—pancreatic cancer	0.00113	0.00156	CcSEcCtD
Apraclonidine—Syncope—Docetaxel—pancreatic cancer	0.00113	0.00156	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—pancreatic cancer	0.00113	0.00156	CcSEcCtD
Apraclonidine—Palpitations—Docetaxel—pancreatic cancer	0.00112	0.00154	CcSEcCtD
Apraclonidine—Hypersensitivity—Irinotecan—pancreatic cancer	0.0011	0.00151	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—pancreatic cancer	0.00109	0.0015	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—pancreatic cancer	0.00109	0.0015	CcSEcCtD
Apraclonidine—Chest pain—Docetaxel—pancreatic cancer	0.00107	0.00148	CcSEcCtD
Apraclonidine—Myalgia—Docetaxel—pancreatic cancer	0.00107	0.00148	CcSEcCtD
Apraclonidine—Nausea—Sunitinib—pancreatic cancer	0.00107	0.00148	CcSEcCtD
Apraclonidine—Asthenia—Irinotecan—pancreatic cancer	0.00107	0.00147	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.00107	0.00147	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—pancreatic cancer	0.00106	0.00146	CcSEcCtD
Apraclonidine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00105	0.00145	CcSEcCtD
Apraclonidine—Dry mouth—Docetaxel—pancreatic cancer	0.00105	0.00145	CcSEcCtD
Apraclonidine—Asthenia—Gemcitabine—pancreatic cancer	0.00104	0.00144	CcSEcCtD
Apraclonidine—Oedema—Docetaxel—pancreatic cancer	0.00103	0.00142	CcSEcCtD
Apraclonidine—Pruritus—Gemcitabine—pancreatic cancer	0.00103	0.00142	CcSEcCtD
Apraclonidine—Infection—Docetaxel—pancreatic cancer	0.00102	0.00141	CcSEcCtD
Apraclonidine—Diarrhoea—Irinotecan—pancreatic cancer	0.00102	0.00141	CcSEcCtD
Apraclonidine—Nervous system disorder—Docetaxel—pancreatic cancer	0.00101	0.00139	CcSEcCtD
Apraclonidine—Pruritus—Fluorouracil—pancreatic cancer	0.00101	0.00139	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—pancreatic cancer	0.00101	0.00139	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—pancreatic cancer	0.00101	0.00139	CcSEcCtD
Apraclonidine—Skin disorder—Docetaxel—pancreatic cancer	0.001	0.00138	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—pancreatic cancer	0.000996	0.00137	CcSEcCtD
Apraclonidine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000993	0.00137	CcSEcCtD
Apraclonidine—Dizziness—Irinotecan—pancreatic cancer	0.000986	0.00136	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—pancreatic cancer	0.000981	0.00135	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00098	0.00135	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—pancreatic cancer	0.000978	0.00135	CcSEcCtD
Apraclonidine—Diarrhoea—Fluorouracil—pancreatic cancer	0.000977	0.00135	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—pancreatic cancer	0.000971	0.00134	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—pancreatic cancer	0.000964	0.00133	CcSEcCtD
Apraclonidine—Vomiting—Irinotecan—pancreatic cancer	0.000948	0.00131	CcSEcCtD
Apraclonidine—Dizziness—Fluorouracil—pancreatic cancer	0.000944	0.0013	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—pancreatic cancer	0.000943	0.0013	CcSEcCtD
Apraclonidine—Dermatitis—Irinotecan—pancreatic cancer	0.000939	0.00129	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000939	0.00129	CcSEcCtD
Apraclonidine—Headache—Irinotecan—pancreatic cancer	0.000934	0.00129	CcSEcCtD
Apraclonidine—Insomnia—Docetaxel—pancreatic cancer	0.000932	0.00128	CcSEcCtD
Apraclonidine—Paraesthesia—Docetaxel—pancreatic cancer	0.000925	0.00128	CcSEcCtD
Apraclonidine—Vomiting—Gemcitabine—pancreatic cancer	0.000923	0.00127	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—pancreatic cancer	0.000921	0.00127	CcSEcCtD
Apraclonidine—Dyspnoea—Docetaxel—pancreatic cancer	0.000919	0.00127	CcSEcCtD
Apraclonidine—Somnolence—Docetaxel—pancreatic cancer	0.000916	0.00126	CcSEcCtD
Apraclonidine—Dermatitis—Gemcitabine—pancreatic cancer	0.000915	0.00126	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—pancreatic cancer	0.000914	0.00126	CcSEcCtD
Apraclonidine—Headache—Gemcitabine—pancreatic cancer	0.00091	0.00125	CcSEcCtD
Apraclonidine—Vomiting—Fluorouracil—pancreatic cancer	0.000908	0.00125	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—pancreatic cancer	0.000907	0.00125	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—pancreatic cancer	0.000905	0.00125	CcSEcCtD
Apraclonidine—Dermatitis—Fluorouracil—pancreatic cancer	0.000899	0.00124	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—pancreatic cancer	0.000898	0.00124	CcSEcCtD
Apraclonidine—Headache—Fluorouracil—pancreatic cancer	0.000894	0.00123	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000892	0.00123	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00089	0.00123	CcSEcCtD
Apraclonidine—Fatigue—Docetaxel—pancreatic cancer	0.000888	0.00122	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—pancreatic cancer	0.000888	0.00122	CcSEcCtD
Apraclonidine—Nausea—Irinotecan—pancreatic cancer	0.000885	0.00122	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000882	0.00122	CcSEcCtD
Apraclonidine—Pain—Docetaxel—pancreatic cancer	0.000881	0.00121	CcSEcCtD
Apraclonidine—Constipation—Docetaxel—pancreatic cancer	0.000881	0.00121	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—pancreatic cancer	0.000874	0.0012	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—pancreatic cancer	0.000872	0.0012	CcSEcCtD
Apraclonidine—Nausea—Gemcitabine—pancreatic cancer	0.000862	0.00119	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—pancreatic cancer	0.000857	0.00118	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—pancreatic cancer	0.000852	0.00117	CcSEcCtD
Apraclonidine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000849	0.00117	CcSEcCtD
Apraclonidine—Nausea—Fluorouracil—pancreatic cancer	0.000848	0.00117	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—pancreatic cancer	0.000846	0.00117	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000843	0.00116	CcSEcCtD
Apraclonidine—Tension—Epirubicin—pancreatic cancer	0.000836	0.00115	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—pancreatic cancer	0.000834	0.00115	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—pancreatic cancer	0.000827	0.00114	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—pancreatic cancer	0.000821	0.00113	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000816	0.00112	CcSEcCtD
Apraclonidine—Abdominal pain—Docetaxel—pancreatic cancer	0.000815	0.00112	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—pancreatic cancer	0.000809	0.00111	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—pancreatic cancer	0.000803	0.00111	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—pancreatic cancer	0.000793	0.00109	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—pancreatic cancer	0.00079	0.00109	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—pancreatic cancer	0.000788	0.00109	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—pancreatic cancer	0.000773	0.00107	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—pancreatic cancer	0.000772	0.00106	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—pancreatic cancer	0.000768	0.00106	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—pancreatic cancer	0.000765	0.00105	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—pancreatic cancer	0.000764	0.00105	CcSEcCtD
Apraclonidine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000759	0.00105	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—pancreatic cancer	0.000753	0.00104	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—pancreatic cancer	0.000743	0.00102	CcSEcCtD
Apraclonidine—Asthenia—Docetaxel—pancreatic cancer	0.000739	0.00102	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000731	0.00101	CcSEcCtD
Apraclonidine—Pruritus—Docetaxel—pancreatic cancer	0.000729	0.001	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—pancreatic cancer	0.000725	0.000999	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—pancreatic cancer	0.000725	0.000999	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00072	0.000992	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—pancreatic cancer	0.000716	0.000987	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—pancreatic cancer	0.000711	0.000979	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—pancreatic cancer	0.000709	0.000977	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—pancreatic cancer	0.000707	0.000974	CcSEcCtD
Apraclonidine—Diarrhoea—Docetaxel—pancreatic cancer	0.000705	0.000972	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—pancreatic cancer	0.000696	0.00096	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—pancreatic cancer	0.000695	0.000958	CcSEcCtD
Apraclonidine—Infection—Epirubicin—pancreatic cancer	0.00069	0.000952	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000682	0.000939	CcSEcCtD
Apraclonidine—Dizziness—Docetaxel—pancreatic cancer	0.000681	0.000939	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—pancreatic cancer	0.000675	0.00093	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—pancreatic cancer	0.000671	0.000925	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—pancreatic cancer	0.000671	0.000925	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000666	0.000918	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—pancreatic cancer	0.000663	0.000913	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—pancreatic cancer	0.000656	0.000904	CcSEcCtD
Apraclonidine—Vomiting—Docetaxel—pancreatic cancer	0.000655	0.000903	CcSEcCtD
Apraclonidine—Dermatitis—Docetaxel—pancreatic cancer	0.000649	0.000895	CcSEcCtD
Apraclonidine—Headache—Docetaxel—pancreatic cancer	0.000645	0.00089	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—pancreatic cancer	0.000643	0.000886	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—pancreatic cancer	0.000639	0.00088	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000633	0.000873	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000631	0.000869	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—pancreatic cancer	0.000629	0.000866	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—pancreatic cancer	0.000625	0.000861	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—pancreatic cancer	0.000624	0.00086	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—pancreatic cancer	0.00062	0.000854	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—pancreatic cancer	0.000618	0.000852	CcSEcCtD
Apraclonidine—Nausea—Docetaxel—pancreatic cancer	0.000612	0.000844	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.0006	0.000827	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—pancreatic cancer	0.000599	0.000826	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—pancreatic cancer	0.000594	0.000819	CcSEcCtD
Apraclonidine—Pain—Epirubicin—pancreatic cancer	0.000594	0.000819	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000586	0.000807	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—pancreatic cancer	0.000582	0.000802	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000577	0.000796	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000573	0.00079	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000573	0.000789	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—pancreatic cancer	0.000572	0.000788	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000568	0.000783	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000555	0.000765	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—pancreatic cancer	0.000554	0.000764	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—pancreatic cancer	0.00055	0.000758	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—pancreatic cancer	0.00055	0.000758	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—pancreatic cancer	0.000549	0.000757	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.00053	0.00073	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000526	0.000725	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000512	0.000706	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000508	0.000701	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—pancreatic cancer	0.000499	0.000687	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—pancreatic cancer	0.000492	0.000678	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—pancreatic cancer	0.000476	0.000655	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000474	0.000653	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—pancreatic cancer	0.000461	0.000636	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—pancreatic cancer	0.00046	0.000633	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—pancreatic cancer	0.000455	0.000627	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—pancreatic cancer	0.000442	0.000609	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—pancreatic cancer	0.00044	0.000606	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—pancreatic cancer	0.000438	0.000603	CcSEcCtD
Apraclonidine—Headache—Epirubicin—pancreatic cancer	0.000435	0.0006	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—pancreatic cancer	0.000425	0.000586	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—pancreatic cancer	0.000413	0.000569	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—pancreatic cancer	0.000409	0.000564	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—pancreatic cancer	0.000405	0.000558	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—pancreatic cancer	0.000403	0.000555	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—pancreatic cancer	0.000382	0.000526	CcSEcCtD
Apraclonidine—ADRA2C—Hemostasis—NRAS—pancreatic cancer	0.000115	0.000419	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TGFB1—pancreatic cancer	0.000114	0.000417	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AGTR1—pancreatic cancer	0.000114	0.000414	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CD44—pancreatic cancer	0.000113	0.00041	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STK11—pancreatic cancer	0.000112	0.000408	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000112	0.000407	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GCG—pancreatic cancer	0.000111	0.000405	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTHLH—pancreatic cancer	0.000111	0.000404	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTCH1—pancreatic cancer	0.000111	0.000404	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SST—pancreatic cancer	0.000109	0.000397	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000108	0.000394	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GCG—pancreatic cancer	0.000108	0.000393	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000108	0.000392	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—TYMS—pancreatic cancer	0.000108	0.000392	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TGFB1—pancreatic cancer	0.000107	0.000389	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JAG1—pancreatic cancer	0.000107	0.000389	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH3—pancreatic cancer	0.000106	0.000387	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AGTR1—pancreatic cancer	0.000106	0.000386	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—KRAS—pancreatic cancer	0.000106	0.000386	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000105	0.000383	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STK11—pancreatic cancer	0.000104	0.000381	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—STK11—pancreatic cancer	0.000102	0.00037	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SST—pancreatic cancer	0.000101	0.000369	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000101	0.000368	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CNR1—pancreatic cancer	0.000101	0.000367	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.99e-05	0.000364	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JAG1—pancreatic cancer	9.91e-05	0.000361	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—KRAS—pancreatic cancer	9.89e-05	0.000361	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH3—pancreatic cancer	9.87e-05	0.00036	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CD—pancreatic cancer	9.82e-05	0.000358	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SMAD4—pancreatic cancer	9.8e-05	0.000357	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CG—pancreatic cancer	9.76e-05	0.000356	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—PIK3CA—pancreatic cancer	9.73e-05	0.000355	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GCG—pancreatic cancer	9.72e-05	0.000354	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—SRC—pancreatic cancer	9.71e-05	0.000354	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CXCL8—pancreatic cancer	9.7e-05	0.000353	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HES1—pancreatic cancer	9.57e-05	0.000349	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—VEGFA—pancreatic cancer	9.45e-05	0.000344	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CD—pancreatic cancer	9.45e-05	0.000344	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CB—pancreatic cancer	9.42e-05	0.000343	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TP53—pancreatic cancer	9.41e-05	0.000343	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CNR1—pancreatic cancer	9.35e-05	0.000341	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—NRAS—pancreatic cancer	9.34e-05	0.00034	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AGTR1—pancreatic cancer	9.27e-05	0.000338	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CB—pancreatic cancer	9.16e-05	0.000334	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SMAD4—pancreatic cancer	9.15e-05	0.000334	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STK11—pancreatic cancer	9.14e-05	0.000333	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—PIK3CA—pancreatic cancer	9.09e-05	0.000331	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CG—pancreatic cancer	9.07e-05	0.000331	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CXCL8—pancreatic cancer	9.06e-05	0.00033	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GCG—pancreatic cancer	9.03e-05	0.000329	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—HRAS—pancreatic cancer	9e-05	0.000328	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HES1—pancreatic cancer	8.94e-05	0.000326	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CXCL8—pancreatic cancer	8.8e-05	0.000321	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TP53—pancreatic cancer	8.79e-05	0.00032	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.78e-05	0.00032	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—APOE—pancreatic cancer	8.74e-05	0.000319	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TYMS—pancreatic cancer	8.73e-05	0.000318	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TGFB1—pancreatic cancer	8.68e-05	0.000316	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AGTR1—pancreatic cancer	8.61e-05	0.000314	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CD—pancreatic cancer	8.58e-05	0.000313	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CB—pancreatic cancer	8.56e-05	0.000312	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STK11—pancreatic cancer	8.49e-05	0.000309	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—HRAS—pancreatic cancer	8.41e-05	0.000306	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TERT—pancreatic cancer	8.38e-05	0.000305	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CB—pancreatic cancer	8.24e-05	0.0003	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CXCL8—pancreatic cancer	8.22e-05	0.0003	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—KRAS—pancreatic cancer	8.04e-05	0.000293	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HIF1A—pancreatic cancer	8.02e-05	0.000292	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SMAD4—pancreatic cancer	8e-05	0.000292	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TSC2—pancreatic cancer	8e-05	0.000291	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CD—pancreatic cancer	7.97e-05	0.000291	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—AKT1—pancreatic cancer	7.95e-05	0.00029	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CXCL8—pancreatic cancer	7.92e-05	0.000288	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CG—pancreatic cancer	7.89e-05	0.000288	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TERT—pancreatic cancer	7.83e-05	0.000285	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOE—pancreatic cancer	7.83e-05	0.000285	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HES1—pancreatic cancer	7.81e-05	0.000285	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KDR—pancreatic cancer	7.67e-05	0.000279	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.65e-05	0.000279	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARG—pancreatic cancer	7.62e-05	0.000277	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HIF1A—pancreatic cancer	7.49e-05	0.000273	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CB—pancreatic cancer	7.48e-05	0.000273	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TSC2—pancreatic cancer	7.47e-05	0.000272	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SMAD4—pancreatic cancer	7.43e-05	0.000271	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—pancreatic cancer	7.43e-05	0.000271	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PIK3CA—pancreatic cancer	7.38e-05	0.000269	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—pancreatic cancer	7.36e-05	0.000268	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOE—pancreatic cancer	7.31e-05	0.000266	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NFKBIA—pancreatic cancer	7.29e-05	0.000266	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HES1—pancreatic cancer	7.26e-05	0.000265	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOTCH1—pancreatic cancer	7.22e-05	0.000263	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—pancreatic cancer	7.19e-05	0.000262	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KDR—pancreatic cancer	7.16e-05	0.000261	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—pancreatic cancer	7.14e-05	0.00026	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOE—pancreatic cancer	7.1e-05	0.000259	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CG—pancreatic cancer	7.06e-05	0.000257	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—NRAS—pancreatic cancer	7.06e-05	0.000257	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGF—pancreatic cancer	6.98e-05	0.000254	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CB—pancreatic cancer	6.95e-05	0.000253	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CD—pancreatic cancer	6.94e-05	0.000253	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TERT—pancreatic cancer	6.85e-05	0.000249	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—HRAS—pancreatic cancer	6.83e-05	0.000249	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NFKBIA—pancreatic cancer	6.81e-05	0.000248	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH1—pancreatic cancer	6.75e-05	0.000246	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	6.68e-05	0.000243	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CG—pancreatic cancer	6.6e-05	0.00024	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—NRAS—pancreatic cancer	6.6e-05	0.00024	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIF1A—pancreatic cancer	6.55e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TSC2—pancreatic cancer	6.53e-05	0.000238	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGF—pancreatic cancer	6.52e-05	0.000238	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—pancreatic cancer	6.44e-05	0.000234	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	6.41e-05	0.000234	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	6.39e-05	0.000233	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	6.36e-05	0.000232	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	6.26e-05	0.000228	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CD—pancreatic cancer	6.21e-05	0.000226	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—pancreatic cancer	6.19e-05	0.000225	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.15e-05	0.000224	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	6.08e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—KRAS—pancreatic cancer	6.08e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	6.07e-05	0.000221	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CB—pancreatic cancer	6.05e-05	0.00022	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—pancreatic cancer	6.03e-05	0.00022	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—pancreatic cancer	6.01e-05	0.000219	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—pancreatic cancer	5.99e-05	0.000218	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	5.96e-05	0.000217	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	5.94e-05	0.000216	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	5.9e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	5.82e-05	0.000212	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CD—pancreatic cancer	5.8e-05	0.000211	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	5.77e-05	0.00021	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	5.77e-05	0.00021	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.74e-05	0.000209	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	5.7e-05	0.000208	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—KRAS—pancreatic cancer	5.68e-05	0.000207	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	5.63e-05	0.000205	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—pancreatic cancer	5.59e-05	0.000204	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	5.53e-05	0.000202	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	5.48e-05	0.0002	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CB—pancreatic cancer	5.41e-05	0.000197	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	5.36e-05	0.000195	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	5.36e-05	0.000195	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	5.3e-05	0.000193	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	5.25e-05	0.000191	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTEN—pancreatic cancer	5.22e-05	0.00019	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—pancreatic cancer	5.22e-05	0.00019	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—pancreatic cancer	5.2e-05	0.00019	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HRAS—pancreatic cancer	5.17e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	5.07e-05	0.000185	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CB—pancreatic cancer	5.06e-05	0.000184	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—pancreatic cancer	5.02e-05	0.000183	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.02e-05	0.000183	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—pancreatic cancer	4.98e-05	0.000181	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	4.96e-05	0.000181	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	4.91e-05	0.000179	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	4.88e-05	0.000178	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—pancreatic cancer	4.87e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—pancreatic cancer	4.86e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCND1—pancreatic cancer	4.85e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HRAS—pancreatic cancer	4.83e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	4.8e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	4.71e-05	0.000172	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	4.7e-05	0.000171	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	4.69e-05	0.000171	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	4.68e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.67e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	4.65e-05	0.000169	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	4.61e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	4.56e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.56e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	4.53e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	4.48e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	4.42e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	4.39e-05	0.00016	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	4.37e-05	0.000159	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	4.34e-05	0.000158	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	4.26e-05	0.000155	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	4.25e-05	0.000155	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTEN—pancreatic cancer	4.24e-05	0.000155	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.24e-05	0.000154	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	4.22e-05	0.000154	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	4.22e-05	0.000154	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	4.18e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	4.17e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	4.11e-05	0.00015	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	4.1e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	4.06e-05	0.000148	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	4.05e-05	0.000148	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	3.96e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	3.95e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	3.95e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	3.92e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	3.92e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	3.91e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	3.9e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	3.89e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	3.88e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	3.84e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	3.82e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	3.81e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	3.8e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	3.78e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	3.73e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	3.69e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	3.68e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	3.64e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	3.63e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	3.62e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	3.59e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	3.57e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	3.55e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	3.55e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	3.54e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	3.46e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	3.45e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	3.42e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	3.41e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	3.35e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	3.3e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	3.29e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	3.2e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	3.19e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	3.17e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	3.17e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	3.17e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	3.17e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	3.1e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	3.08e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	3.05e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—pancreatic cancer	3.01e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	2.99e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	2.98e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	2.95e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	2.94e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	2.93e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	2.88e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	2.85e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	2.72e-05	9.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	2.7e-05	9.82e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.69e-05	9.82e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	2.61e-05	9.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	2.52e-05	9.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.5e-05	9.12e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	2.49e-05	9.08e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—pancreatic cancer	2.45e-05	8.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	2.42e-05	8.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	2.32e-05	8.44e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	2.2e-05	8.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	2.04e-05	7.45e-05	CbGpPWpGaD
